Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Krutika Joshi, Ph.D., D.B.Sc.

Title
Institution
Department
Address
Phone

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Zhdanava M, Karkare S, Pilon D, Joshi K, Rossi C, Morrison L, Sheehan J, Lefebvre P, Lopena O, Citrome L. Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drug-Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant Depression. Adv Ther. 2021 Sep; 38(9):4900-4916. PMID: 34368919.
    Citations:    Fields:    
  2. Mahabaleshwarkar R, Lin D, Joshi K, Fishman J, Blair T, Hetherington T, Palmer P, Patel C, Krull C, Tcheremissine OV. Characteristics and Healthcare Burden of Patients with Schizophrenia Treated in a US Integrated Healthcare System. J Ment Health Policy Econ. 2021 Jun 01; 24(2):47-59. PMID: 34151777.
    Citations:    Fields:    Translation:Humans
  3. Szukis H, Joshi K, Huang A, Amos TB, Wang L, Benson CJ. Economic burden of treatment-resistant depression among veterans in the United States. Curr Med Res Opin. 2021 Aug; 37(8):1393-1401. PMID: 33879005.
    Citations:    Fields:    
  4. Karkare S, Nash A, Han E, Sheehan JJ, Near A, Banerji T, Zhao X, Aboumrad M, Joshi K. Baseline Characteristics and Current Standard of Care (SOC) Among US Veterans with Major Depressive Disorder (MDD). CNS Spectr. 2021 04; 26(2):174-175. PMID: 34127087.
    Citations:    Fields:    
  5. Pilon D, Joshi K, Sheehan JJ, Zichlin ML, Zuckerman P, Lefebvre P, Greenberg PE. Correction: Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis. PLoS One. 2021; 16(4):e0249731. PMID: 33793676.
    Citations:    Fields:    
  6. Zhdanava M, Pilon D, Ghelerter I, Chow W, Joshi K, Lefebvre P, Sheehan JJ. The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States. J Clin Psychiatry. 2021 03 16; 82(2). PMID: 33989464.
    Citations:    Fields:    
  7. Patel C, Emond B, Morrison L, Lafeuille MH, Lefebvre P, Lin D, Kim E, Joshi K. Risk of subsequent relapses and corresponding healthcare costs among recently-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study. Curr Med Res Opin. 2021 04; 37(4):665-674. PMID: 33507831.
    Citations: 1     Fields:    
  8. Lin D, Pilon D, Zhdanava M, Joshi K, Lafeuille MH, Côté-Sergent A, Vermette-Laforme M, Lefebvre P. Medication adherence, healthcare resource utilization, and costs among Medicaid beneficiaries with schizophrenia treated with once-monthly paliperidone palmitate or once-every-three-months paliperidone palmitate. Curr Med Res Opin. 2021 04; 37(4):675-683. PMID: 33507838.
    Citations:    Fields:    
  9. Voelker J, Joshi K, Daly E, Papademetriou E, Rotter D, Sheehan JJ, Kuvadia H, Liu X, Dasgupta A, Potluri R. How well do clinical and demographic characteristics predict Patient Health Questionnaire-9 scores among patients with treatment-resistant major depressive disorder in a real-world setting? Brain Behav. 2021 02; 11(2):e02000. PMID: 33403828.
    Citations:    Fields:    Translation:Humans
  10. Zhdanava M, Kuvadia H, Joshi K, Daly E, Pilon D, Rossi C, Morrison L, Lefebvre P, Nelson C. Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder. Curr Med Res Opin. 2021 01; 37(1):123-133. PMID: 33124940.
    Citations: 2     Fields:    Translation:Humans
  11. Zhdanava M, Kuvadia H, Joshi K, Daly E, Pilon D, Rossi C, Morrison L, Lefebvre P, Nelson C. Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions. J Manag Care Spec Pharm. 2020 Aug; 26(8):996-1007. PMID: 32552362.
    Citations: 2     Fields:    Translation:Humans
  12. Shrestha A, Roach M, Joshi K, Sheehan JJ, Goutam P, Everson K, Heerlein K, Jena AB. Incremental Health Care Burden of Treatment-Resistant Depression Among Commercial, Medicaid, and Medicare Payers. Psychiatr Serv. 2020 06 01; 71(6):593-601. PMID: 32237982.
    Citations: 1     Fields:    Translation:Humans
  13. Pilon D, Szukis H, Joshi K, Singer D, Sheehan JJ, Wu JW, Lefebvre P, Greenberg P. US Integrated Delivery Networks Perspective on Economic Burden of Patients with Treatment-Resistant Depression: A Retrospective Matched-Cohort Study. Pharmacoecon Open. 2020 Mar; 4(1):119-131. PMID: 31254275.
    Citations: 1     
  14. Pilon D, Joshi K, Sheehan JJ, Zichlin ML, Zuckerman P, Lefebvre P, Greenberg PE. Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis. PLoS One. 2019; 14(10):e0223255. PMID: 31600244.
    Citations: 3     Fields:    Translation:Humans
  15. Patel C, El Khoury A, Huang A, Wang L, Baser O, Joshi K. Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis. Adv Ther. 2019 10; 36(10):2941-2953. PMID: 31396809.
    Citations:    Fields:    Translation:Humans
  16. Song X, El Khoury AC, Brouillette M, Smith D, Joshi K. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia. J Med Econ. 2019 Nov; 22(11):1105-1112. PMID: 31062998.
    Citations: 1     Fields:    Translation:Humans
  17. Pilon D, Sheehan JJ, Szukis H, Morrison L, Zhdanava M, Lefebvre P, Joshi K. Is clinician impression of depression symptom severity associated with incremental economic burden in privately insured US patients with treatment resistant depression? J Affect Disord. 2019 08 01; 255:50-59. PMID: 31128505.
    Citations: 1     Fields:    Translation:Humans
  18. DerSarkissian M, Lefebvre P, Joshi K, Brown B, Lafeuille MH, Bhak RH, Hellstern M, Bobbili P, Shiner B, El Khoury AC, Young-Xu Y. Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans. Clin Ther. 2018 09; 40(9):1496-1508. PMID: 30145029.
    Citations: 2     Fields:    Translation:Humans
  19. Huang A, Amos TB, Joshi K, Wang L, Nash A. Understanding healthcare burden and treatment patterns among young adults with schizophrenia. J Med Econ. 2018 Oct; 21(10):1026-1035. PMID: 30001651.
    Citations: 4     Fields:    Translation:Humans
  20. Joshi K, Muser E, Xu Y, Schwab P, Datar M, Suehs B. Adherence and economic impact of paliperidone palmitate versus oral atypical antipsychotics in a Medicare population. J Comp Eff Res. 2018 08; 7(8):723-735. PMID: 29722547.
    Citations: 2     Fields:    Translation:Humans
  21. Kamstra R, Pilon D, Lefebvre P, Emond B, Joshi K. Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics. Curr Med Res Opin. 2018 08; 34(8):1377-1388. PMID: 29452492.
    Citations: 1     Fields:    Translation:Humans
  22. Joshi K, Mao L, Biondi DM, Millet R. The Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations, Outcomes (REACH-OUT) study: real-world clinical practice in schizophrenia. BMC Psychiatry. 2018 01 29; 18(1):24. PMID: 29378547.
    Citations: 2     Fields:    Translation:Humans
  23. Pilon D, Tandon N, Lafeuille MH, Kamstra R, Emond B, Lefebvre P, Joshi K. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics. Clin Ther. 2017 Oct; 39(10):1972-1985.e2. PMID: 28919292.
    Citations: 12     Fields:    Translation:Humans
  24. Joshi K, Lafeuille MH, Kamstra R, Tiggelaar S, Lefebvre P, Kim E, Yue Y, Tandon N. Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits. J Comp Eff Res. 2018 02; 7(2):121-133. PMID: 28809128.
    Citations: 4     Fields:    Translation:Humans
  25. Joshi K, Lafeuille MH, Brown B, Wynant W, Emond B, Lefebvre P, Tandon N. Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting. Curr Med Res Opin. 2017 10; 33(10):1763-1772. PMID: 28741387.
    Citations: 5     Fields:    Translation:Humans
  26. Pilon D, Muser E, Lefebvre P, Kamstra R, Emond B, Joshi K. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia. BMC Psychiatry. 2017 06 02; 17(1):207. PMID: 28576133.
    Citations: 6     Fields:    Translation:Humans
  27. Joshi K, Lin J, Lingohr-Smith M, Fu DJ, Muser E. Treatment Patterns and Antipsychotic Medication Adherence Among Commercially Insured Patients With Schizoaffective Disorder in the United States. J Clin Psychopharmacol. 2016 Oct; 36(5):429-35. PMID: 27525965.
    Citations: 4     Fields:    Translation:Humans
  28. Joshi K, Pan X, Wang R, Yang E, Benson C. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate. Curr Med Res Opin. 2016 11; 32(11):1873-1881. PMID: 27479694.
    Citations: 3     Fields:    Translation:Humans
  29. Benson CJ, Joshi K, Lapane KL, Fastenau J. Evaluation of a comprehensive information and assistance program for patients with schizophrenia treated with long-acting injectable antipsychotics. Curr Med Res Opin. 2015; 31(7):1437-48. PMID: 25978698.
    Citations: 1     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Joshi's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (70)
Explore
_
Co-Authors (1)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.